Published November 28, 2025
| Version v1
Journal article
Open
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC
Authors/Creators
- Pulido, I.
- Garcia-Canaveras, J. C.
- Rodriguez, M. L.
- Becker, J. H.
- Lopez, A.
- Aupi, M.1
- Aparisi, S.
- Chulia-Peris, L.
- Tamayo-Torres, E.
- Carreres-Rey, C.
- Fernandez-Coronado, J. Alcacer
-
Benet, M.2
- Montero, S.
- Mena, S.
-
Sandoval, J.2
- Pereda, J.
- Alcacer, J.
- Calabuig-Farinas, S.
- Jantus-Lewintre, E.
- Cremades, A.
- Galbis-Caravajal, J. M.
- Martin-Martorell, P.
- Insa, A.
- Massad, Malek G.
-
Juan-Vidal, O.2
-
Lahoz, A.2
- Shimamura, T.
- Carretero, J.
- 1. Department of Surgery, Division of Cardiothoracic Surgery
- 2. Biomarkers and Precision Medicine Unit and Analytic Unit, Health Research Institute Hospital La Fe
Description
Lung cancer is the deadliest neoplasia worldwide. Despite the
availability of targeted therapies like tyrosine kinase inhibitors
(TKIs) for EGFR-driven tumours in Non-Small Cell Lung Cancer (NSCLC),
drug resistance remains a major factor that dramatically cuts life
expectancy. Here we identify how increased expression of nicotinamide
N-methyltransferase (NNMT) in TKI-resistant cancer cells diverts
nicotinamide to synthesise 1-Methylnicotinamide (1-MNA) and lowers NAD+
levels that generates a druggable nicotinamide phosphoribosyltransferase
(NAMPT) metabolic vulnerability. We also report that high blood levels
of 1-MNA, the byproduct of NNMT activity, are significantly associated
with lower survival rates in EGFR TKI-treated NSCLC patients. Taken
together, our findings describe a new and highly specific non-genetic
metabolic synthetic lethality for mesenchymal-like tumours, which
exposes NAMPT as an in vivo druggable target and establishes 1-MNA as a
novel liquid biopsy biomarker to predict and monitor EGFR TKI resistance
in NSCLC.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.